This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy

This study has been completed.
Bangkok Drug company
Information provided by (Responsible Party):
Kongkiat Kulkantrakorn, Thammasat University Identifier:
First received: October 7, 2009
Last updated: May 8, 2012
Last verified: May 2012
Painful diabetic neuropathy is the most common cause of neuropathic pain. 0.075% topical capsaicin has been used to treat the pain, but there is no data in lower concentration. This is the efficacy and safety of 0.025% topical capsaicin in treatment of painful diabetic polyneuropathy.

Condition Intervention Phase
Diabetic Polyneuropathy Drug: Capsaicin Drug: placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy

Resource links provided by NLM:

Further study details as provided by Kongkiat Kulkantrakorn, Thammasat University:

Primary Outcome Measures:
  • Pain relief from pain score reduction, using visual analog scale (VAS) [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC) [ Time Frame: 8 weeks ]

Enrollment: 33
Study Start Date: October 2009
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Capsaicin Drug: Capsaicin
0.025% topical capsaicin applied 4 times per day for 8 weeks
Other Name: Capsika gel
Placebo Comparator: placebo Drug: placebo
vehicle gel, applied 4 times per day for 8 weeks

Detailed Description:

Patient is randomized to receive either 0.025% topical capsaicin or vehicle control (placebo) for 8 weeks. After one week wash-out period, patients will be switched to the other group for 8 weeks.

Outcome will be assessed by visual analog scale, neuropathic pain scale, SF-MPQ, SF-36. Safety and tolerability will be recorded.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of type 2 Diabetes mellitus
  • Peripheral neuropathy
  • Stabilized on pain medication for at least one month
  • No previous invasive intervention for pain relief

Exclusion Criteria:

  • Local wound or skin abnormality in the applicable area
  • Allergic to capsaicin
  • Refuse to participate or give consent
  • Has other significant disease or receive medication that may worsen neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00993070

Thammasat University Hospital
Pathumthani, Thailand, 12120
Sponsors and Collaborators
Thammasat University
Bangkok Drug company
Principal Investigator: Kongkiat Kulkantrakorn, MD Thammasat University
  More Information

Responsible Party: Kongkiat Kulkantrakorn, Associate Professor, Thammasat University Identifier: NCT00993070     History of Changes
Other Study ID Numbers: MTU-I-1-45/52
Study First Received: October 7, 2009
Last Updated: May 8, 2012

Keywords provided by Kongkiat Kulkantrakorn, Thammasat University:
diabetic polyneuropathy
neuropathic pain

Additional relevant MeSH terms:
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs processed this record on June 23, 2017